Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$103.36 +0.8%	$106.65	$72.21 ▼ $139.13	$5.09B	0.47	671,645 shs	1.18 million shs
MESO Mesoblast	$10.92 +1.6%	$11.31	$5.78 ▼ $22.00	$1.40B	2.41	275,415 shs	165,213 shs
NUVL Nuvalent	$79.68 +0.7%	$74.73	$55.54 ▼ $113.51	$5.72B	1.34	500,733 shs	2.07 million shs
VRNA Verona Pharma PLC American Depositary Share	$93.82 -0.6%	$78.39	$14.15 ▼ $99.01	$7.99B	0.21	1.26 million shs	951,387 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	+0.77%	+2.65%	+0.36%	-12.80%	+34.02%
MESO Mesoblast	+1.58%	+4.60%	-0.27%	-9.83%	+64.46%
NUVL Nuvalent	+0.70%	+6.24%	+11.55%	+9.08%	+1.14%
VRNA Verona Pharma PLC American Depositary Share	-0.61%	-0.53%	+26.90%	+49.63%	+538.67%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AXSM Axsome Therapeutics	4.6229 of 5 stars	4.5	1.0	4.5	1.3	4.2	0.6
MESO Mesoblast	1.6347 of 5 stars	3.5	1.0	0.0	1.6	0.8	0.6
NUVL Nuvalent	2.6507 of 5 stars	3.5	3.0	0.0	2.0	3.3	0.0
VRNA Verona Pharma PLC American Depositary Share	1.7905 of 5 stars	2.5	1.0	0.0	3.5	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXSM Axsome Therapeutics	3.06	Buy	$172.33	66.73% Upside
MESO Mesoblast	3.00	Buy	$18.00	64.84% Upside
NUVL Nuvalent	2.92	Moderate Buy	$119.60	50.10% Upside
VRNA Verona Pharma PLC American Depositary Share	3.00	Buy	$101.10	7.76% Upside

Current Analyst Ratings Breakdown

Latest MESO, AXSM, NUVL, and VRNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	NUVL Nuvalent	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$105.00 ➝ $112.00
6/24/2025	NUVL Nuvalent	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$115.00
6/24/2025	NUVL Nuvalent	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$125.00 ➝ $140.00
6/24/2025	NUVL Nuvalent	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$110.00 ➝ $130.00
6/23/2025	VRNA Verona Pharma PLC American Depositary Share	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$76.00 ➝ $160.00
6/20/2025	VRNA Verona Pharma PLC American Depositary Share	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$107.00 ➝ $138.00
6/18/2025	VRNA Verona Pharma PLC American Depositary Share	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$92.00 ➝ $116.00
6/12/2025	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$193.00 ➝ $186.00
6/11/2025	VRNA Verona Pharma PLC American Depositary Share	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$90.00 ➝ $100.00
6/11/2025	VRNA Verona Pharma PLC American Depositary Share	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$95.00 ➝ $110.00
6/10/2025	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$180.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXSM Axsome Therapeutics	$385.69M	13.20	N/A	N/A	$1.18 per share	87.59
MESO Mesoblast	$5.90M	236.50	N/A	N/A	$4.21 per share	2.59
NUVL Nuvalent	N/A	N/A	N/A	N/A	$14.99 per share	N/A
VRNA Verona Pharma PLC American Depositary Share	$42.28M	188.90	N/A	N/A	$2.56 per share	36.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXSM Axsome Therapeutics	-$287.22M	-$5.77	N/A	36.65	N/A	-64.39%	-272.80%	-36.69%	8/4/2025 (Estimated)
MESO Mesoblast	-$87.96M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/29/2025 (Estimated)
NUVL Nuvalent	-$260.76M	-$4.39	N/A	N/A	N/A	N/A	-31.35%	-29.27%	8/14/2025 (Estimated)
VRNA Verona Pharma PLC American Depositary Share	-$173.42M	-$2.00	N/A	3,127.33	N/A	N/A	-69.65%	-28.00%	8/6/2025 (Estimated)

Latest MESO, AXSM, NUVL, and VRNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/8/2025	Q1 2025	NUVL Nuvalent	-$1.14	-$1.18	-$0.04	-$1.18	N/A	N/A
4/29/2025	Q1 2025	VRNA Verona Pharma PLC American Depositary Share	-$0.22	$0.27	+$0.49	-$0.16	$41.47 million	$98.65 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
MESO Mesoblast	N/A	N/A	N/A	N/A	N/A
NUVL Nuvalent	N/A	N/A	N/A	N/A	N/A
VRNA Verona Pharma PLC American Depositary Share	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXSM Axsome Therapeutics	3.48	2.03	1.96
MESO Mesoblast	0.22	0.96	0.63
NUVL Nuvalent	N/A	14.48	14.48
VRNA Verona Pharma PLC American Depositary Share	1.07	8.86	8.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXSM Axsome Therapeutics	81.49%
MESO Mesoblast	1.43%
NUVL Nuvalent	97.26%
VRNA Verona Pharma PLC American Depositary Share	85.88%

Insider Ownership

Company	Insider Ownership
AXSM Axsome Therapeutics	22.30%
MESO Mesoblast	18.80%
NUVL Nuvalent	10.20%
VRNA Verona Pharma PLC American Depositary Share	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXSM Axsome Therapeutics	380	49.24 million	38.26 million	Optionable
MESO Mesoblast	80	127.78 million	103.76 million	Optionable
NUVL Nuvalent	40	71.81 million	64.48 million	Optionable
VRNA Verona Pharma PLC American Depositary Share	30	85.13 million	81.05 million	Optionable

MESO, AXSM, NUVL, and VRNA Headlines

Recent News About These Companies

SG Americas Securities LLC Takes Position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)

June 26 at 3:20 AM | marketbeat.com

HBK Sorce Advisory LLC Sells 3,800 Shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)

June 25 at 7:35 AM | marketbeat.com

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Reaches New 52-Week High on Analyst Upgrade

June 25 at 2:19 AM | americanbankingnews.com

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Hits New 52-Week High After Analyst Upgrade

June 23, 2025 | marketbeat.com

Piper Sandler Forecasts Strong Price Appreciation for Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Stock

June 23, 2025 | marketbeat.com

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Shares Sold by PFG Investments LLC

June 22, 2025 | marketbeat.com

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Price Target Raised to $138.00 at Wells Fargo & Company

June 21, 2025 | americanbankingnews.com

Roth Capital Hikes Verona Pharma’s (VRNA) Price Target to $116 On COPD Market Prospects

June 20, 2025 | msn.com

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Given New $138.00 Price Target at Wells Fargo & Company

June 20, 2025 | marketbeat.com

Roth Capital Reiterates Buy Rating for Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)

June 20, 2025 | americanbankingnews.com

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) General Counsel Andrew Fisher Sells 80,000 Shares of Stock

June 19, 2025 | insidertrades.com

Mission Wealth Management LP Purchases New Stake in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)

June 19, 2025 | marketbeat.com

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) General Counsel Sells $922,400.00 in Stock

June 18, 2025 | marketbeat.com

Verona Pharma: An Impressive Initial Launch

June 18, 2025 | seekingalpha.com

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Receives "Buy" Rating from Roth Capital

June 18, 2025 | marketbeat.com

Verona Pharma (NASDAQ:VRNA) Hits New 12-Month High - What's Next?

June 16, 2025 | marketbeat.com

Traders Purchase High Volume of Verona Pharma Put Options (NASDAQ:VRNA)

June 16, 2025 | marketbeat.com

Jefferies Backs Verona Pharma plc (VRNA) After Strong Ohtuvayre Launch

June 14, 2025 | finance.yahoo.com

Verona Pharma plc (NASDAQ:VRNA) CEO Sells $4,560,000.00 in Stock

June 14, 2025 | insidertrades.com

Verona Pharma plc (NASDAQ:VRNA) CEO Sells $4,560,000.00 in Stock

June 13, 2025 | marketbeat.com

Verona Pharma plc (NASDAQ:VRNA) CFO Mark W. Hahn Sells 400,000 Shares

June 13, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MESO, AXSM, NUVL, and VRNA Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

$103.36 +0.79 (+0.77%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$103.42 +0.06 (+0.05%)

As of 06/27/2025 07:01 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Mesoblast NASDAQ:MESO

$10.92 +0.17 (+1.58%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$10.92 0.00 (-0.01%)

As of 06/27/2025 04:13 PM Eastern

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Nuvalent NASDAQ:NUVL

$79.68 +0.55 (+0.70%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$79.70 +0.02 (+0.03%)

As of 06/27/2025 04:44 PM Eastern

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Verona Pharma PLC American Depositary Share NASDAQ:VRNA

$93.82 -0.58 (-0.61%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$93.51 -0.31 (-0.33%)

As of 06/27/2025 07:59 PM Eastern

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time